Healthcare provider profile · identity verified

Danilo Morejon Carbonell

Nurse Practitioner · TAMARAC, FL · NPI 1437727948

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	512	177
Losartan Potassium	Losartan Potassium	240	89
Amlodipine Besylate	Amlodipine Besylate	222	86
Rosuvastatin Calcium	Rosuvastatin Calcium	221	88
Lisinopril	Lisinopril	201	69
Metformin Hcl	Metformin Hcl	200	69
Levothyroxine Sodium	Levothyroxine Sodium	197	73
Vitamin D2	Ergocalciferol (Vitamin D2)	164	58
Pantoprazole Sodium	Pantoprazole Sodium	153	64
Azithromycin	Azithromycin	148	129
Albuterol Sulfate Hfa	Albuterol Sulfate	147	70
Gabapentin	Gabapentin	145	52
Diclofenac Sodium	Diclofenac Sodium	123	87
Fluticasone Propionate	Fluticasone Propionate	115	69
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	88	60
Ciprofloxacin Hcl	Ciprofloxacin Hcl	87	79
Metoprolol Succinate	Metoprolol Succinate	81	26
Omeprazole	Omeprazole	81	43
Escitalopram Oxalate	Escitalopram Oxalate	80	28
Hydrochlorothiazide	Hydrochlorothiazide	76	28
Meclizine Hcl	Meclizine Hcl	72	44
Tamsulosin Hcl	Tamsulosin Hcl	72	23
Famotidine	Famotidine	70	33
Triamcinolone Acetonide	Triamcinolone Acetonide	67	40
Sildenafil Citrate	Sildenafil Citrate	58	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	57	53
Montelukast Sodium	Montelukast Sodium	53	24
Alendronate Sodium	Alendronate Sodium	51	19
Glipizide	Glipizide	47	14
Eliquis	Apixaban	46	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	46	12
Folic Acid	Folic Acid	45	14
Metoprolol Tartrate	Metoprolol Tartrate	44	19
Fenofibrate	Fenofibrate Nanocrystallized	43	22
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	43	34
Prednisone	Prednisone	43	22
Tramadol Hcl	Tramadol Hcl	43	31
Baclofen	Baclofen	42	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	42	20
Xarelto	Rivaroxaban	42	suppressed
Ezetimibe	Ezetimibe	39	15
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	38	33
Furosemide	Furosemide	37	19
Glimepiride	Glimepiride	37	11
Simvastatin	Simvastatin	37	15
Trazodone Hcl	Trazodone Hcl	37	11
Quetiapine Fumarate	Quetiapine Fumarate	35	suppressed
Januvia	Sitagliptin Phosphate	34	suppressed
Meloxicam	Meloxicam	34	32
Alprazolam	Alprazolam	33	24
Clopidogrel	Clopidogrel Bisulfate	33	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	33	31
Carvedilol	Carvedilol	32	12
Tradjenta	Linagliptin	32	suppressed
Tizanidine Hcl	Tizanidine Hcl	31	24
Mupirocin	Mupirocin	30	28
Valsartan	Valsartan	29	13
Duloxetine Hcl	Duloxetine Hcl	27	12
Lactulose	Lactulose	27	14
Levofloxacin	Levofloxacin	27	25
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	27	25
Olmesartan Medoxomil	Olmesartan Medoxomil	27	suppressed
Acetic Acid	Acetic Acid	26	24
Glipizide Er	Glipizide	26	suppressed
Ibuprofen	Ibuprofen	26	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Methylprednisolone	Methylprednisolone	26	24
Naproxen	Naproxen	25	19
Novolog Mix 70-30 Flexpen	Insulin Aspart Prot/Insuln Asp	25	suppressed
Sertraline Hcl	Sertraline Hcl	24	suppressed
Benzonatate	Benzonatate	23	18
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Myrbetriq	Mirabegron	22	suppressed
Tadalafil	Tadalafil	22	suppressed
Temazepam	Temazepam	22	suppressed
Ketoconazole	Ketoconazole	20	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Mometasone Furoate	Mometasone Furoate	19	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Metformin Hcl Er	Metformin Hcl	18	11
Nifedipine Er	Nifedipine	18	suppressed
Procto-Med Hc	Hydrocortisone	18	12
Valacyclovir	Valacyclovir Hcl	18	16
Ammonium Lactate	Ammonium Lactate	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Atenolol	Atenolol	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Latanoprost	Latanoprost	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	14
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	15	suppressed
Finasteride	Finasteride	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Calcium Acetate	Calcium Acetate	14	suppressed
Advocate Pen Needle	Pen Needle, Diabetic	13	suppressed
Allopurinol	Allopurinol	13	suppressed
Amoxicillin	Amoxicillin	13	12
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	13	suppressed
Ciclopirox	Ciclopirox Olamine	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Ozempic	Semaglutide	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error